FDA Brief

Warning letters Drugs

FDA warning letter to

Stellalife, Inc.

High riskIssued Sep 16, 2025Posted Sep 23, 2025Center for Drug Evaluation and Research (CDER)

FDA told Stellalife its homeopathic oral care gels and rinses are unapproved new drugs sold without FDA approval.

What happened

FDA reviewed the company's website (www.stellalife.com) in July 2025 and also looked at its Instagram, Facebook and YouTube accounts, which send consumers to the site to buy. FDA said the product labeling claims the gels and rinses speed healing after dental surgery, relieve pain and swelling, and kill bacteria that cause periodontal disease, which makes them drugs, and that no FDA-approved applications exist for them. FDA also noted the products are marketed to children and to patients at high risk of infection, and that the contract manufacturer recalled several lots in June 2023 and June 2024 because of microbial contamination.

What FDA found

  1. The website and social media claims show the products are meant to prevent, treat or cure disease, which makes them drugs under the law.

    Section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1); 21 CFR 201.128
  2. The products are not generally recognized as safe and effective for the uses on their labels, so they are 'new drugs'.

    Section 201(p) of the FD&C Act, 21 U.S.C. 321(p)
  3. The products are sold in interstate commerce without an FDA-approved drug application.

    Sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d)
  4. Labeling as a homeopathic drug does not exempt a product from the drug approval, adulteration or misbranding requirements.

    Section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)

What FDA wants

FDA asks the company to write to CDER's Office of Unapproved Drugs and Labeling Compliance within 15 working days describing the specific steps taken to correct the violations and prevent them from happening again, with supporting documents. If corrections cannot be finished in that time, the company must explain the delay and say when they will be done.

Who should pay attention

  • dental practices and oral surgeons that recommend or apply these products
  • distributors and retailers that stock homeopathic oral care products
  • brands that rely on the same contract manufacturer for their own labeled products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk